{"id":"W2908639608","doi":"10.1016/j.ygyno.2018.12.009","title":"Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial","year":2019,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; BC Cancer Agency","funders":"Medac; Clovis Oncology; Russian Science Foundation; Merck KGaA; Teva Pharmaceutical Industries; Genentech; PharmaMar; Mersana Therapeutics; AstraZeneca; Eli Lilly and Company; Amgen","keywords":"Medicine; Hazard ratio; Internal medicine; Ovarian cancer; Adverse effect; Population; Clinical endpoint; Placebo; Surgery; Anemia; Randomized controlled trial; Confidence interval; Cancer; Oncology; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003939452,0.0002184691,0.0007095262,0.00007582112,0.00003980119,0.000006699809,0.0001352403,0.0002439969,0.0008427109],"category_scores_gemma":[0.0002802448,0.0001316025,0.00006248149,0.0002331285,0.000223278,0.00004080446,0.00004928557,0.0002821439,0.00004149069],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00102055,"about_ca_system_score_gemma":0.0006243583,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001617643,"about_ca_topic_score_gemma":0.001944889,"domain_scores_codex":[0.9979937,0.0003073256,0.000610824,0.000524324,0.0002133421,0.0003504831],"domain_scores_gemma":[0.9973553,0.001604353,0.0004043138,0.0004400258,0.0001067967,0.00008916382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5091513,0.005399222,0.1932564,0.00002706084,0.0005471525,0.0001246923,0.006346874,0.0001129002,0.0003915409,0.0006364274,0.003701187,0.2803052],"study_design_scores_gemma":[0.2854264,0.01587366,0.6477721,0.0001516714,0.00008721906,0.000006096399,0.0001960142,0.00001806748,0.0001397702,0.0001547532,0.05003126,0.0001430285],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866237,0.0002773281,0.000006733695,0.003734876,0.001085316,0.003429429,0.0001834195,0.00002600853,0.004633157],"genre_scores_gemma":[0.9966037,0.001096574,0.0002857769,0.00109066,0.0001757254,0.0002598291,0.0001219384,0.00001776911,0.0003480865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4545157,"threshold_uncertainty_score":0.9227093,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02799214301805251,"score_gpt":0.3271328342064086,"score_spread":0.2991406911883561,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}